医学
中医药
传统医学
替代医学
焦虑
萧条(经济学)
心理健康
精神科
病理
经济
宏观经济学
作者
Qiong Wang,Shenghan Gao,Wensheng Zhang,Yong Zhao,Yan He,Wei Sun,Fenglian Zhang,Yu Tao,Lihong Zhou,Zhengliang Ye,Jiansen Su,Shunnan Zhang,Yongfa Chen
出处
期刊:PubMed
日期:2022-04-10
卷期号:77 (3): 125-130
被引量:1
摘要
Mental health disorders such as stress, anxiety, depression and insomnia caused by COVID-19 have attracted worldwide attention. Traditional Chinese medicines (TCMs) have been proven to be a safe and effective option for treating mental health disorders. Recently, after assessing its efficacy and safety fully, the Netherlands Medicines Evaluation Board approved XiaoYao Tablets as a traditional herbal medicinal product (THMP), indicated for an alternative self-care for patients in Europe to relieve the symptoms of mental stress and exhaustion. Despite the fact that TCMs have gradually become one of the therapeutic choices worldwide, to-date, only a few TCMs have been successfully registered in the European Union (EU) as THMPs, and XiaoYao Tablets is the first successfully registered combination TCM from China. In this article, traditional use efficacy and clinical safety of XiaoYao Tablets in the treatment of mental health disorders were summarized and analyzed from the perspective of traditional use registration (TUR). Additionally a safety evolution pathway of combination TCMs was established. This article will not only seek to enhance our understanding about traditional use efficacy and clinical safety of XiaoYao Tablets, but also summarize the experience of XiaoYao Tablets as the first successfully registered combination TCM from China, which could serve as role model for the others to overcome registration difficulties in the EU.
科研通智能强力驱动
Strongly Powered by AbleSci AI